Oncology development
What the Anktiva Plus BCG Trial Shows in BCG-Naïve Bladder Cancer
QUILT-2.005 met its six-month complete response endpoint in BCG-naïve bladder cancer. See what the topline leaves open and how sites capture the endpoint.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
On November 9, 2026, ImmunityBio reported that adding Anktiva to bacillus Calmette-Guérin (BCG) improved the six-month complete response rate versus BCG alone in Cohort A of QUILT-2.005. The randomized, open-label study evaluated patients with high-grade non-muscle-invasive bladder cancer (NMIBC) who were new to BCG and had carcinoma in situ (CIS), with or without papillary tumors. The sponsor reported 370 randomized patients and more than 75 participating sites. The result supports a planned U.S. filing for earlier use, with response rates by arm still to be presented. [1–3]
What the six-month endpoint measures
The primary endpoint asks how many participants had a complete response at six months. Sites assess response with cystoscopy, urine cytology and confirmatory bladder biopsy when required. A separate cohort enrolls patients with high-grade papillary-only disease and evaluates disease-free survival. The November announcement covers Cohort A, the CIS population. [2–4]
Both groups received BCG directly into the bladder. The combination added Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist that activates natural killer cells and certain T cells. The comparison tests what adding this therapy contributes to the BCG regimen. [1–3, 5]
What will determine the clinical impact
The sponsor reported a statistically significant difference and said the combination’s median duration of response had yet to be reached. It described the most common adverse events as consistent with BCG alone, reported no treatment-related deaths and said patient-reported quality of life was maintained. The announcement leaves the absolute response difference, confidence intervals, follow-up by arm and detailed safety and quality-of-life results for a fuller presentation. [1, 3]
Longer follow-up can show whether a six-month response holds and how often patients later need another intervention, progress to muscle-invasive disease or undergo bladder removal. Reports should distinguish the share of all randomized patients who are in response at a later visit from the duration of response among those who responded. Both help clinicians discuss how likely a benefit is and how long it may last.
Where the combination could fit in U.S. care
The FDA’s October 2026 expansion added high-grade papillary-only tumors to the existing Anktiva-plus-BCG indication for adults with BCG-unresponsive NMIBC. ImmunityBio plans a supplemental application by the end of 2026 for BCG-naïve use, which remains investigational. If approved, the combination could give eligible patients another option administered directly into the bladder at the start of BCG-based treatment. [1, 6]
The FDA approved durvalumab plus BCG in May 2026 for BCG-naïve, high-risk NMIBC, based on disease-free survival in POTOMAC. QUILT-2.005 used BCG alone as its control and measured six-month complete response in patients with CIS. The different populations and endpoints limit what clinicians can infer across studies. Access also depends on BCG supply and a clinic’s capacity for repeated instillations and surveillance. The FDA lists TICE BCG as available, with allocation when demand exceeds planned supply. [2, 7, 8]
What this means for trial teams
Rehearse the assessment before site activation. In a hypothetical case, a patient completes cystoscopy and cytology in the visit window, but an outside lab has yet to return a required biopsy report. Ask the site to show where it records the procedure date, how it tracks the report, who owns the follow-up and how the investigator documents the assessment. A late report and a late procedure call for different actions under the protocol. [2, 9]
Track why assessments remain incomplete. Use Lampgen’s SIGNAL™ framework to compare completion and reasons for delay across sites. Distinguish capacity for procedure appointments, transportation barriers and delays in returning outside records. The CRA verifies source and escalates under the monitoring plan. The study manager can give the relevant team an action and check whether the next set of visits shows improvement. This is the site-level judgment Lampgen looks for when staffing oncology CRAs. [9–11]
Sources
- ImmunityBio, QUILT-2.005 topline disclosure filed with the SEC, November 9, 2026
- UK Health Research Authority, QUILT-2.005 protocol summary and endpoints
- Urology Times, QUILT-2.005 topline reporting, November 9, 2026
- ClinicalTrials.gov, QUILT-2.005 trial registration NCT02138734
- DailyMed, Anktiva U.S. prescribing information, October 2026
- FDA, expanded Anktiva indication in BCG-unresponsive NMIBC, October 2026
- FDA, durvalumab plus BCG approval and POTOMAC efficacy results, May 2026
- FDA, current biologic supply and TICE BCG allocation
- FDA, ICH E6(R3) Good Clinical Practice final guidance
- Lampgen Clinical Insights, trial participation burden and patient access
- Lampgen Clinical Research, a worked SIGNAL™ monitoring case